150 related articles for article (PubMed ID: 26050359)
1. Evaluation of the human papillomavirus mRNA test for the detection of cervical lesions in Japan.
Nakayama Y; Yamada M; Kurata A; Kiseki H; Isaka K; Kuroda M
Eur J Gynaecol Oncol; 2015; 36(2):192-6. PubMed ID: 26050359
[TBL] [Abstract][Full Text] [Related]
2. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions.
Dockter J; Schroder A; Hill C; Guzenski L; Monsonego J; Giachetti C
J Clin Virol; 2009 Jul; 45 Suppl 1():S55-61. PubMed ID: 19651370
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
[TBL] [Abstract][Full Text] [Related]
4. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
[TBL] [Abstract][Full Text] [Related]
5. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
Zhang H; Varma KR; Han M; Matsko J; Zhao C
Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
[TBL] [Abstract][Full Text] [Related]
7. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
[TBL] [Abstract][Full Text] [Related]
8. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.
Arbyn M; Roelens J; Cuschieri K; Cuzick J; Szarewski A; Ratnam S; Reuschenbach M; Belinson S; Belinson JL; Monsonego J
Int J Cancer; 2013 Jan; 132(1):101-8. PubMed ID: 22610699
[TBL] [Abstract][Full Text] [Related]
9. Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions.
Virtanen E; Kalliala I; Dyba T; Nieminen P; Auvinen E
Acta Obstet Gynecol Scand; 2017 Jan; 96(1):61-68. PubMed ID: 27858961
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.
Sandri MT; Lentati P; Benini E; Dell'Orto P; Zorzino L; Carozzi FM; Maisonneuve P; Passerini R; Salvatici M; Casadio C; Boveri S; Sideri M
J Clin Microbiol; 2006 Jun; 44(6):2141-6. PubMed ID: 16757611
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.
Wu R; Belinson SE; Du H; Na W; Qu X; Wu R; Liu Y; Wang C; Zhou Y; Zhang L; Belinson JL
Int J Gynecol Cancer; 2010 Nov; 20(8):1411-4. PubMed ID: 21051986
[TBL] [Abstract][Full Text] [Related]
14. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
[TBL] [Abstract][Full Text] [Related]
15. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
17. Clinical performance of a human papillomavirus messenger RNA test (Aptima HPV Assay) on residual material from archived 3-year-old PreservCyt samples with low-grade squamous intraepithelial lesion.
Waldstrøm M; Ornskov D
Arch Pathol Lab Med; 2011 Aug; 135(8):1052-6. PubMed ID: 21809999
[TBL] [Abstract][Full Text] [Related]
18. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
[No Abstract] [Full Text] [Related]
19. Comparison of the performance of HPV tests in women with abnormal cytology: results of a study within the NHS cervical screening programme.
Moss SM; Bailey A; Cubie H; Denton K; Sargent A; Muir P; Vipond IB; Winder R; Kitchener H
Cytopathology; 2015 Dec; 26(6):373-80. PubMed ID: 25274541
[TBL] [Abstract][Full Text] [Related]
20. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results.
Reuschenbach M; Clad A; von Knebel Doeberitz C; Wentzensen N; Rahmsdorf J; Schaffrath F; Griesser H; Freudenberg N; von Knebel Doeberitz M
Gynecol Oncol; 2010 Oct; 119(1):98-105. PubMed ID: 20619445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
